Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione clinical trials

Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations

This study looks at a new treatment called amivantamab with chemotherapy for people with a specific type of lung cancer (NSCLC) where standard treatments haven't worked well. It aims to see how many people respond to the treatment.